Hepatitis C virus (HCV), a hepatotropic, non-cytopathic, positive-strand RNA virus that belongs to the *Flaviviridae* family, is a major cause of chronic liver disease[@b1]. An estimated 180 million people are carriers of HCV[@b2]. Approximately 80% of infected patients fail to clear the virus and progress to chronic hepatitis. Some of those with chronic HCV infection may progress to liver cirrhosis and eventually hepatocellular carcinoma (HCC)[@b3], which ranks as the fifth most common cancer in the world[@b4]. Genotype 4 (HCV-G4) is the prevalent genotype in Egypt[@b5], the Kingdom of Saudi Arabia[@b6], and Africa[@b7]. Egypt has the highest HCV prevalence in the world, with an overall prevalence of 12% among the general population, 40% in persons above 40 years of age, and even higher among persons in rural areas[@b8]. Some studies have indicated a link between HCV-G4 and the frequency and development of HCC[@b9].

Cytokines, as the products of host response to inflammation, play an important role in the defense against viral infections[@b10]. The maximum capacity of cytokine production in individuals has a major genetic component[@b11]. Polymorphisms within the regulatory regions or signal sequences of cytokine genes have been shown to affect the overall expression and secretion of cytokines both *in vitro* and sporadically *in vivo* systems[@b12]. Associations between polymorphisms in cytokine genes and inflammation, allograft rejection, autoimmune, and infectious diseases have been reported[@b12]--[@b15].

Tumor necrosis factor-alpha (TNF-α), a potent antiviral cytokine with a wide range of proinflammatory activities[@b16], plays a pivotal role in host immune response to HCV infection because cytotoxic T lymphocytes (CTLs) in the liver secrete TNF-α[@b17]. Circulating TNF-α level increases during HCV infection[@b18]--[@b20], and hepatitis viral infection induces TNF-α production in human hepatocytes[@b21]. An elevated TNF-α level correlates with the severity of hepatic inflammation, fibrosis, and tissue injury[@b19],[@b22]--[@b24]. Persistent immune-mediated hepatic injury can initiate the process of fibrosis, cirrhosis, and, eventually, HCC[@b22],[@b25]--[@b27].

TNF-α expression is tightly controlled at the transcriptional and post-transcriptional levels[@b12]. Six diallelic polymorphisms in the *TNF*-α promoter, which are thought to affect TNF-α production, have been reported and occur at positions -1031, -863, -857, -376, -308, and -238[@b12],[@b28],[@b29]. Polymorphism in the human TNF-α promoter at -308[@b30] involves the substitution of adenosine for guanine in the uncommon alleles. A variety of infectious diseases and inflammatory disorders are associated with TNF-α -308 alleles[@b31]. The role of polymorphisms in TNF-α in the pathogenesis of HCV infection has been investigated, but some results are contradictory[@b32]--[@b36]. These discrepancies may be due to ethnic differences in the examined populations, leading to a differential distribution of cytokine gene polymorphisms.

We hypothesized that genetic variability in *TNF*-α -308 alleles may account for different susceptibility to HCV infection. Therefore, this study was designed to investigate the role of the -308G/A polymorphism in the *TNF*-α promoter in the progression of HCV infection in Egyptian patients.

Materials and Methods {#s2}
=====================

Study population {#s2a}
----------------

Of consecutive Egyptian patients with chronic HCV infection who were admitted to the Tropical Medicine Department, Ain Shams University Hospital, Cairo, Egypt, 90 patients were studied: 45 had HCV-induced cirrhosis and 45 had HCC. As controls, 45 age-matched healthy Egyptian volunteers, with no history of liver disease, normal liver function tests, and no evidence of HCV infection (confirmed by PCR), were enrolled. Informed consent was obtained from all study subjects. The local ethics committee at Ain Shams University approved the study protocol. All investigations were performed in accordance with the Health and Human Ethical Clearance Committee guidelines for clinical studies, Menofiya University.

All participants were subjected to thorough history taking and clinical examinations. HCV antibody assay was performed using third-generation enzyme-linked immunosorbent assay (ELISA) (Murex Biotech Ltd.) and confirmed by reverse transcription-polymerase chain reaction using the Amplicore HCV assay (Roche Diagnostics Corp., Indianapolis, IN) and hepatitis B surface antigen (HBsAg) (Sorin Biomedica Co., Italy). All patient groups were HCV antibody- and HCV RNA-positive and were negative for HBsAg and schistosome infection. No patients underwent antiviral therapy, and none had a history of habitual alcohol consumption. Exclusion criteria included co-infection with hepatitis B virus (HBV) and/or schistosome infection.

Serologic testing {#s2b}
-----------------

Serum levels of albumin, total bilirubin, direct bilirubin, alanine aminotransferase (ALT), alkaline phosphatase (ALP), and aspartate aminotransferase (AST) were tested. The diagnosis of cirrhosis was based on the presence of clinical manifestations of portal hypertension such as varices, encephalopathy, or ascites; biochemical abnormalities including elevated serum bilirubin, decreased serum albumin, or prolonged prothrombin time; and obvious morphologic change of the liver detected by hepatic imaging such as ultrasonography.

HCC diagnosis {#s2c}
-------------

The diagnosis of HCC was made after reviewing images generated with several imaging modalities. Nodules larger than 1 cm found in the ultrasound screening of a cirrhotic liver were investigated further with either 4-phase multidetector computed tomography (CT) scan or dynamic contrast-enhanced magnetic resonance imaging (MRI). If the appearances were typical of HCC, namely, hypervascular in the arterial phase with washout in the portal venous or delayed phase, the lesion was diagnosed as HCC. If the findings were not characteristic or the vascular profile was not typical, a second contrast-enhanced study with the other imaging modality was performed or the lesion was biopsied. All patients were confirmed not to have other cancers in an initial screening examination[@b37],[@b38].

DNA extraction {#s2d}
--------------

Genomic DNA was isolated from 200 µL of whole blood using the silica membrane spin column based kit (Qiagen, Hilden, Germany) according to manufacturer\'s instructions.

Polymorphism genotyping {#s2e}
-----------------------

*TNF*-α (-308G/A) SNP genotyping was performed using Assays-by-Design SM for SNP Genotyping (TaqMan® MGB probes, FAM™ and VIC® dye-labeled) (Applied Biosystems). The TNF-α -308 Custom TaqMan® SNP Genotyping assay (number 4331349) was performed in a 48-well plate format on a one-step unit (Applied Biosystems). Amplification was performed in a 25 µL volume reaction. The following cycling conditions were used: 10 min at 94°C, 15 s at 92°C, and 1 min at 60°C for 40 cycles.

TNF-α measurement {#s2f}
-----------------

Serum levels of TNF-α were quantified using an ELISA that follows the quantitative sandwich immunoassay technique. This assay used immobilized monoclonal antibody and biotin-linked polyclonal antibody, both of which were specific for human TNF-α. Commercially available matched and paired antibodies were used (R&D Systems Inc. Minneapolis, MN, USA). A total of 50 µL of anti-human monoclonal antibody (4 g/mL) was coated onto each well of a 96-well flat bottom microtiter plate (Griener Labortechnik, Kremsmunster, Austria) and incubated for 1 h at 37°C, then overnight at 4°C in a humidified chamber. Plates were washed three times with washing buffer, phosphate-buffered saline (PBS)/0.05% polyoxyethylene-20 (Tween-20), and blocked with 200 µL/well blocking buffer, PBS/0.05% Tween-20/5% fetal bovine serum (FBS) (Sigma Co., St. Louis, MO, USA) at 37°C for 1.5 h. For TNF-α level quantification, triplicate assays of 50 µL aliquots of patient serum samples and recombinant human TNF-α standards (R&D Systems) were incubated for 1 h at 37°C. At the end of the incubation, the plates were washed three times with washing buffer and incubated in diluted secondary antibody, biotin-labeled anti-human TNF-α polyclonal antibody (200 ng/mL), for 1 h at 37°C. After washing away any unbound substances, 50 µL of peroxidase-conjugated streptavidin (Jackson Immun-search Lab, USA), which was diluted at 1:1000, was added to each well, and the plates were incubated for 1 h at 37°C. After intensive washing, the enzyme reaction was carried out by adding 50 µL of substrate solution \[equal volumes of 3,3′,5,5′-tetramethyl benzidine (TMB; 0.4 g/L) and H~2~O~2~ (0.02% in citric acid buffer; KPL, Kirkegaard and Perry Lab, Gaithersburg, MD, USA) to each well. Color development was stopped by addition of 50 µL/well of stopping buffer (1 mol/L HCI) (Surechern Products, Needham Marker, Suffolk, England). The intensity of the developed color was measured by reading optical absorbance at 450 nm using a microplate reader (FLUOstar OPTIMA, BMG LABTECH GmbH, Offenburg, Germany). The microplate reader software (Softmax) readily processed the raw absorbance values into a standard curve from which TNF-α concentration of unknown samples could be derived directly.

Statistical analysis {#s2g}
--------------------

All statistical analyses was performed using the Statistical Package for Social Science (SPSS) version 10 (LEAD Technology Inc). Data are presented as means with corresponding standard error (SE). Comparisons among different groups were performed by one-way analysis of variance (ANOVA). The Tukey test was used as a post-hoc test. Frequency was compared between groups using the Chi-square test. Correlation between variables was determined using Pearson\'s correlation test. In all tests, the level of significance was *P* \< 0.05.

Results {#s3}
=======

Demographic and clinical information of patients and controls {#s3a}
-------------------------------------------------------------

The demographic characteristics of the subjects enrolled are given in [Table 1](#cjc-31-01-029-t01){ref-type="table"}. Of the 90 HCV-infected patients, 69 were men and 21 were women, with an age ranged from 42 to 70 years; 45 had cirrhosis, and 45 had HCC. Of the 45 healthy controls, 21 were men and 24 were women, with an age ranged from 34 to 70 years, without any history of liver disease. The age of the patients was positively correlated to the progression of the disease (*r*=0.526, *P* \< 0.001).

TNF-α genotype {#s3b}
--------------

The distribution of genotypes for *TNF*-α at position -308 are given in [Table 2](#cjc-31-01-029-t02){ref-type="table"}. The SNP frequency at the *TNF*-α -308 position was significantly different between HCV-infected patients and healthy individuals (*P*\<0.001). On the other hand, no significant difference in the SNP frequency at the *TNF*-α -308 position was recorded between patients with cirrhosis or HCC. The frequency of the G allele was significantly higher in HCV-infected patients than in healthy controls (*P*\<0.05), whereas the frequency of the A allele was significantly higher in healthy controls than in HCV-infected patients (*P*\<0.001).

HCV infection and serum TNF-α level {#s3c}
-----------------------------------

Compared with those in healthy controls, serum TNF-α levels were gradually elevated in HCV-infected patients (*P*\<0.001) ([Figure 1](#cjc-31-01-029-g001){ref-type="fig"}). Patients with HCC had significantly higher TNF-α levels than patients with cirrhosis (*P*\<0.001). The serum level of TNF-α was positively correlated to the severity of the HCV infection (*r*=0.691, *P*\<0.001).

###### Demographic and clinical characteristics of the studied population

  Parameter                      Healthy controls (*n* = 45)   Cirrhosis patients (*n =* 45)   HCC patients (*n =* 45)            *P*             Correlation with disease progression
  ----------------------------- ----------------------------- ------------------------------- ------------------------- ------------------------ --------------------------------------
  Gender (♂/♀)                              21/24                          33/12                        36/9                     \<0.01          
  Age (years)                              44 ± 3                         54 ± 2                       58 ± 2                   \<0.001                  *r*= 0.526, *P*\<0.001
  (34-70)                                  (42-62)                        (43-70)                                        *r*= 0.480, *P*\<0.001  
  Comma(pre / negative)                   Negative                         15/30                        24/21                   \<0.001          
  Ascites (moderate/negative)             Negative                         18/27                        18/27                   \<0.001                  *r*= 0.369, *P*\<0.001
  INR                                    1.16 ±0.03                     1.25 ±0.03                   1.48 ± 0.05                \<0.001                  *r*= 0.443, *P*\<0.001
  ALT (IU/L)                             21.66 ±0.76                   43.53 ± 2.77                 67.33 ± 4.88                \<0.001                  *r*= 0.650, *P*\<0.001
  AST(IU/L)                             28.66 ± 1.04                   68.95 ± 4.48                 90.08 ± 5.54                \<0.001                  *r*= 0.679, *P*\<0.001
  ALP (IU/L)                             68.46 ±1.59                   86.66 ± 3.40                 99.53 ± 4.57                \<0.001                  *r*= 0.488, *P*\<0.001
  Albumin (g/L)                          4.13 ± 0.08                    2.66 ± 0.11                  2.78 ± 0.10                \<0.001                 *r*= -0.615, *P*\<0.001
  Bilirubin                                                                                                                                      
   Total (µmol/L)                        0.94 ± 0.04                    1.70 ±0.10                   1.64 ± 0.10                \<0.001                  *r*= 0.423, *P*\<0.01
   Direct (µmol/L)                       0.16 ± 0.01                    0.75 ± 0.06                  0.50 ± 0.04                \<0.001                  *r*= 0.382, *P*\<0.01
  HCV                                                                                                                                            
   Ab                                     Negative                       Positive                     Positive                                   
   PCR                                    Negative                       Positive                     Positive                                   
   HBsAg                                  Negative                       Negative                     Negative                                   

HCC, hepatocellular carcinoma; ALT, alinine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; INR, international normalization ratio; HCV, hepatitis C virus. All data are presented as mean ± standard error (SE). Differences among the 3 groups were compared by ANOVA test.

###### Distribution of *TNF*-α genotypes and frequencies in HCV-infected patients and healthy controls

  Genotype             Healthy controls (*n* = 45)   Cirrhosis patients (*n* = 45)   HCC patients (*n* = 45)
  ------------------- ----------------------------- ------------------------------- -------------------------
  -308 G/A genotype                                                                 
   G/G                           25 (56)                      39 (87)^a^                   42 (94)^a^
   G/A                           13 (29)                       3 (7)^b^                     2 (4)^a^
   A/A                           7 (15)                          3 (6)                      1 (2)^c^
   GA+AA                         38 (84)                      42 (93)^a^                   44 (97)^a^
  -308 G/A alleles                                                                  
   G                             63 (70)                        81 (90)                    86 (96)^c^
   A                             27 (30)                       9 (10)^a^                    4 (4)^a^

All data are presented as cases (%). ^a^*P*\< 0.001, ^b^*P* \< 0.01, ^c^*P* \< 0.05, vs. controls.

Discussion {#s4}
==========

The promoter of *TNF*-α has many biallelic variations, and the one at position -308 (G-308A), relative to the transcription start site[@b39], has been linked with several inflammatory, autoimmune, infectious, and malignant diseases[@b40]. The impact of host genetic factors and the polymorphism at the -308 position on the clinical outcome of HCV infection have not been fully elucidated. Thus, this study examined the influence of genetic variation on the regulation of TNF-α and disease progression.

The role of polymorphisms in proinflammatory cytokines is unclear. Although one report indicates that the *TNF2* allele is more frequently found in patients with cirrhosis than in those with less severe liver disease[@b32], another study has not confirmed these results[@b41]. In the current study, we found significant difference in the distribution of *TNF*-α promoter polymorphism at position -308 between HCV-infected patients enrolled in this work. Our results are consistent with those reported by Zein *et al.*[@b42], but quite different from another study[@b43]. SNPs at -308 showed inconsistent associations with various HCV outcomes[@b32],[@b44],[@b45]. The -308A promoter variant has been associated with enhanced transcription of TNF-α [@b12], but other investigations have failed to confirm this finding[@b46]. In a previous study, no significant difference was observed in the frequency of the TNF-α -308.2 allele at position -308, which had been linked formerly to higher TNF-α production[@b12]. Likewise, another study did not find the SNP at -308 to be associated with viral recovery or persistence[@b35]. Yee et al.[@b32] found that -308A was associated with increased cirrhosis in HCV-infected patients.

![Serum levels of tumor necrosis factor-α (TNF-α) in hepatitis C virus (HCV)-infected patients. Data are presented as box plots with lines inside the box representing medians, boxes representing 25^th^ and 75^th^ percentiles and the lines outside the boxes indicating 10^th^ and 90^th^ percentiles. HCC, hepatocellular carcinoma.](cjc-31-01-029-g001){#cjc-31-01-029-g001}

In considering the relationship between *TNF*-α -308 polymorphisms and the severity of disease, Barrett *et al.*[@b35] and Hohler *et al.*[@b45] reported an association between these factors in patients with chronic HCV infection; Romero-Gomez *et al.*[@b47] found no association between *TNF*-α -308 polymorphisms and the severity of fibrosis in HCC. Hence, studies of *TNF*-α -308 polymorphisms and its effect on TNF-α production have been inconsistent but nevertheless indicate that this position likely influences the production of TNF-α, which may in turn affect the outcome of an HCV infection. Similarly, functional studies of the allele -308A polymorphism have been inconsistent, with both higher[@b48] and unchanged[@b49] TNF-α production in cells stimulated with lipopolysac-charide. Yee *et al.* [@b32] showed that *TNF*-α -308.2 conferred a 5.1-fold risk of cirrhosis for patients with chronic HCV infection. No correlation between *TNF*-α -308 promoter polymorphisms and necroinflammatory histological activity was previously demonstrated.

Hepatocyte damage elicits an inflammatory response through activation of tissue macrophage Kupffer cells. These activated cells release an array of antiviral cytokines including TNF-α, which plays a pivotal role in host immune response to HCV infection. In this study, elevated TNF-α levels were seen in HCV-infected patients with HCC compared to healthy controls. We previously reported elevation of TNF-α levels in HCV-infected patients[@b50]. These results are consistent with known mechanisms involved in the progression of chronic HCV infection, including activation of proinflammatory cytokines by the virus[@b11]. In accordance with our results, circulating TNF-α level has been reported to increase during HCV infection[@b18]--[@b20],[@b22]. An elevated TNF-α level has been correlated with the severity of hepatic inflammation, fibrosis, and tissue injury[@b19],[@b22]--[@b24]. Moreover, TNF-α plays an important role in hepatic fibrogenesis and progression of fibrosis in chronic liver disease[@b22],[@b24].

Our results showed a significant elevation in serum TNF-α levels in patients with HCC, well above those of patients with cirrhosis. Chronic HCV infection has been well established as an independent risk factor for HCC[@b34],[@b35]. As with oncogenic viruses, chronic HCV infection may lead to persistent hepatocyte necroinflammation and hepatic fibrosis[@b17],[@b26]--[@b27]. Persistent immune-mediated hepatic injury can initiate the process of fibrosis, cirrhosis, and, eventually, HCC[@b17],[@b22],[@b25]--[@b27]. In conclusion, this preliminary study indicated that inheritance of the TNF-α promoter genotype at position -308 is not associated with clinical features of HCV infection. However, one of the shortcomings of this study is its rather small sample size; therefore, the results should be confirmed in a larger series, as well as in patients of different ethnic origins. Based on these findings, further analysis of polymorphisms in other immune response genes in a large study population is required to understand the consequence of gene variants in HCV infection.
